2022
Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial
Branch-Elliman W, Ferguson R, Doros G, Woods P, Leatherman S, Strymish J, Datta R, Goswami R, Jankowich MD, Shah NR, Taylor TH, Page ST, Schiller SJ, Shannon C, Hau C, Flynn M, Holmberg E, Visnaw K, Dhond R, Brophy M, Monach PA. Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: A pragmatic, embedded randomized clinical trial. PLOS ONE 2022, 17: e0263591. PMID: 35213547, PMCID: PMC8880885, DOI: 10.1371/journal.pone.0263591.Peer-Reviewed Original ResearchConceptsStandard of careSubcutaneous sarilumabMechanical ventilationSevere COVID-19 diseaseHospitalized COVID-19 patientsDays of randomizationIL-6R inhibitionRate of intubationTrial of patientsSevere COVID-19COVID-19 patientsNumber of patientsVA Medical CenterAnti-inflammatory drugsCOVID-19SARS-CoV-2COVID-19 diseaseData monitoring committeeEligible patientsPrimary endpointSOC armPrimary outcomeRespiratory compromiseElectronic health record systemsClinical criteria
2021
517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial
Branch-Elliman W, Ferguson R, Doros G, Woods P, Leatherman S, Strymish J, Datta R, Goswami R, Jankowich M, Shah N, Taylor T, Page S, Schiller S, Shannon C, Hau C, Flynn M, Holmberg E, Visnaw K, Dhond R, Brophy M, Monach P. 517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial. Open Forum Infectious Diseases 2021, 8: 360-360. PMCID: PMC8690689, DOI: 10.1093/ofid/ofab466.716.Peer-Reviewed Original ResearchSubcutaneous sarilumabStandard careMechanical ventilationLearning healthcare systemClinical trialsSevere COVID-19 diseaseCOVID-19Rate of intubationSevere COVID-19Trial of patientsCare clinical trialsIL-6 inhibitionTreatment of patientsNumber of patientsStandard of careHealthcare systemEvidence of benefitCOVID-19 diseaseData monitoring committeeA PragmaticPrimary endpointChart reviewHospitalized patientsPrimary outcomeSupplemental oxygen